Kingworld Medicines Group Ltd. (HK:1110)
:1110
Top Page
Kingworld Medicines Group Ltd.
(1110)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$0.60
▲(12.64% Upside)
Action:ReiteratedDate:10/22/25
Kingworld Medicines Group Ltd. has a stable financial foundation with effective cost management and a strong balance sheet. However, concerns about cash flow volatility and liquidity management, combined with mixed technical indicators and a high P/E ratio, suggest caution. The high dividend yield is a positive aspect, but the overall valuation remains a concern.
Positive Factors
Balance Sheet Strength
A solid balance sheet and stable equity ratio indicate structural financial stability, reducing insolvency risk and enabling multi-quarter investments in manufacturing, regulatory compliance, or product development without immediate reliance on external funding, supporting resilience.
Negative Factors
Revenue Decline
A roughly 10.8% revenue decline signals weakening top-line momentum that can erode scale advantages and pressure long-term margins. If persistent, this reduces internal funding for R&D and commercialization, making strategic growth and market share retention harder.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A solid balance sheet and stable equity ratio indicate structural financial stability, reducing insolvency risk and enabling multi-quarter investments in manufacturing, regulatory compliance, or product development without immediate reliance on external funding, supporting resilience.
Read all positive factors
Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$294.15M
Dividend Yield5.87%
Average Volume (3M)1.11M
Price to Earnings (P/E)24.9
Beta (1Y)0.27
Revenue Growth-10.78%
EPS Growth-82.81%
CountryHK
Employees972
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.03
Shares Outstanding622,499,940
10 Day Avg. Volume874,800
30 Day Avg. Volume1,111,766
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)0.38
Price to Sales (P/S)0.23
P/FCF Ratio2.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kingworld Medicines Group Ltd. Business Overview & Revenue Model
Company Description
Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products. The company also supplies pharmaceutical, healthcare, general foodstuffs, and medical products. It offers produc...
How the Company Makes Money
Kingworld Medicines Group Ltd. generates revenue through multiple streams, primarily by selling its proprietary herbal medicines and healthcare products to wholesalers, retailers, and directly to consumers. The company benefits from a diversified ...
Kingworld Medicines Group Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 939.84M | 1.06B | 1.08B | 957.70M | 847.39M | 745.38M |
| Gross Profit | 235.23M | 270.45M | 280.67M | 277.63M | 263.60M | 280.15M |
| EBITDA | 56.63M | 100.46M | 125.48M | 118.07M | 116.00M | 120.59M |
| Net Income | 5.43M | 41.56M | 38.10M | 22.74M | 30.32M | 11.72M |
Balance Sheet | ||||||
| Total Assets | 1.40B | 1.42B | 1.34B | 1.26B | 1.21B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 254.85M | 249.60M | 194.03M | 256.17M | 198.41M | 261.46M |
| Total Debt | 434.48M | 402.44M | 354.43M | 290.68M | 238.96M | 305.78M |
| Total Liabilities | 701.11M | 710.04M | 638.30M | 569.15M | 493.19M | 576.86M |
| Stockholders Equity | 616.42M | 639.79M | 619.03M | 615.58M | 616.90M | 591.80M |
Cash Flow | ||||||
| Free Cash Flow | -7.83M | 94.73M | -63.25M | 93.64M | 22.88M | 113.66M |
| Operating Cash Flow | -21.66M | 135.82M | 42.28M | 186.55M | 81.20M | 123.58M |
| Investing Cash Flow | 40.88M | -27.64M | -120.63M | -84.05M | -50.84M | -2.76M |
| Financing Cash Flow | -74.00M | -47.61M | 4.37M | -51.31M | -87.20M | 25.03M |
Kingworld Medicines Group Ltd. Technical Analysis
Negative
0.53
Price Trends
0.52
Negative
0.52
Negative
0.54
Negative
Market Momentum
>-0.01
Positive
35.10
Neutral
40.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.53 is above the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.52, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.10 is Neutral, neither overbought nor oversold. The STOCH value of 40.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.
Kingworld Medicines Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$376.08M | 9.52 | 5.03% | 1.12% | -16.52% | -8.87% | |
59 Neutral | HK$1.45B | 21.20 | 3.91% | ― | -15.96% | 32.95% | |
56 Neutral | HK$294.15M | 24.91 | 0.86% | 5.87% | -10.78% | -82.81% | |
53 Neutral | HK$236.91M | 15.20 | -5.18% | 28.00% | -1.68% | -111.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$926.38M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
44 Neutral | HK$208.55M | -3.96 | -11.18% | ― | -19.28% | -42.27% |
* Healthcare Sector Average
HK:1110
Kingworld Medicines Group Ltd.
0.49
0.04
10.23%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.07
-42.26%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
2.01
1.75
673.08%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.26
1.02
425.00%
HK:3390
Tycoon Group Holdings Limited
0.27
-3.07
-92.04%
HK:6833
Sinco Pharmaceuticals Holdings Ltd.
0.19
0.01
5.71%
Kingworld Medicines Group Ltd. Corporate Events
Kingworld Medicines Signs MOU for HK$66 Million Pharma Manufacturing Acquisition
Jan 22, 2026
Kingworld Medicines Group Limited has announced that its wholly owned subsidiary, Kingworld Medicine (BVI), has entered into a non-legally binding memorandum of understanding to acquire a pharmaceutical manufacturing company that also owns certain...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.